| pubmed-article:14666628 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:14666628 | lifeskim:mentions | umls-concept:C0024623 | lld:lifeskim |
| pubmed-article:14666628 | lifeskim:mentions | umls-concept:C0246415 | lld:lifeskim |
| pubmed-article:14666628 | lifeskim:mentions | umls-concept:C0085405 | lld:lifeskim |
| pubmed-article:14666628 | lifeskim:mentions | umls-concept:C0282460 | lld:lifeskim |
| pubmed-article:14666628 | lifeskim:mentions | umls-concept:C0205179 | lld:lifeskim |
| pubmed-article:14666628 | pubmed:issue | 5b | lld:pubmed |
| pubmed-article:14666628 | pubmed:dateCreated | 2003-12-11 | lld:pubmed |
| pubmed-article:14666628 | pubmed:abstractText | Docetaxel (DCT), a semisynthetic taxoid, has demonstrated cytotoxic activity against gastric cancer in early phase II studies producing an overall response rate of 17-24%. The Gruppo Oncologico Italia Meridionale (G.O.I.M.) started a confirmatory multicenter phase II trial to evaluate the clinical activity and toxicity of single agent TXT in the treatment of advanced gastric cancer patients who had failed a first-line chemotherapy. | lld:pubmed |
| pubmed-article:14666628 | pubmed:language | eng | lld:pubmed |
| pubmed-article:14666628 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:14666628 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:14666628 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:14666628 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:14666628 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:14666628 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:14666628 | pubmed:issn | 0250-7005 | lld:pubmed |
| pubmed-article:14666628 | pubmed:author | pubmed-author:CatalanoGiuse... | lld:pubmed |
| pubmed-article:14666628 | pubmed:author | pubmed-author:ColucciGiusep... | lld:pubmed |
| pubmed-article:14666628 | pubmed:author | pubmed-author:GiulianiFranc... | lld:pubmed |
| pubmed-article:14666628 | pubmed:author | pubmed-author:GebbiaVittori... | lld:pubmed |
| pubmed-article:14666628 | pubmed:author | pubmed-author:MaielloEvaris... | lld:pubmed |
| pubmed-article:14666628 | pubmed:author | pubmed-author:De... | lld:pubmed |
| pubmed-article:14666628 | pubmed:author | pubmed-author:Di... | lld:pubmed |
| pubmed-article:14666628 | pubmed:author | pubmed-author:GebbiaNicoloN | lld:pubmed |
| pubmed-article:14666628 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:14666628 | pubmed:volume | 23 | lld:pubmed |
| pubmed-article:14666628 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:14666628 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:14666628 | pubmed:pagination | 4219-22 | lld:pubmed |
| pubmed-article:14666628 | pubmed:dateRevised | 2004-11-17 | lld:pubmed |
| pubmed-article:14666628 | pubmed:meshHeading | pubmed-meshheading:14666628... | lld:pubmed |
| pubmed-article:14666628 | pubmed:meshHeading | pubmed-meshheading:14666628... | lld:pubmed |
| pubmed-article:14666628 | pubmed:meshHeading | pubmed-meshheading:14666628... | lld:pubmed |
| pubmed-article:14666628 | pubmed:meshHeading | pubmed-meshheading:14666628... | lld:pubmed |
| pubmed-article:14666628 | pubmed:meshHeading | pubmed-meshheading:14666628... | lld:pubmed |
| pubmed-article:14666628 | pubmed:meshHeading | pubmed-meshheading:14666628... | lld:pubmed |
| pubmed-article:14666628 | pubmed:meshHeading | pubmed-meshheading:14666628... | lld:pubmed |
| pubmed-article:14666628 | pubmed:meshHeading | pubmed-meshheading:14666628... | lld:pubmed |
| pubmed-article:14666628 | pubmed:meshHeading | pubmed-meshheading:14666628... | lld:pubmed |
| pubmed-article:14666628 | pubmed:meshHeading | pubmed-meshheading:14666628... | lld:pubmed |
| pubmed-article:14666628 | pubmed:meshHeading | pubmed-meshheading:14666628... | lld:pubmed |
| pubmed-article:14666628 | pubmed:articleTitle | Docetaxel as salvage therapy in advanced gastric cancer: a phase II study of the Gruppo Oncologico Italia Meridionale (G.O.I.M.). | lld:pubmed |
| pubmed-article:14666628 | pubmed:affiliation | Medical and Experimental Oncology Unit, Oncology Institute, Bari, Italy. | lld:pubmed |
| pubmed-article:14666628 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:14666628 | pubmed:publicationType | Clinical Trial | lld:pubmed |
| pubmed-article:14666628 | pubmed:publicationType | Multicenter Study | lld:pubmed |
| pubmed-article:14666628 | pubmed:publicationType | Clinical Trial, Phase II | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:14666628 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:14666628 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:14666628 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:14666628 | lld:pubmed |
